A prospective randomized trial of FK506-based immunosuppression after renal transplantation

R ShapiroS Mitchell


A group of 204 adult patients was entered into a prospective, randomized trial comparing FK506/prednisone with FK506/azathioprine/prednisone after renal transplantation between August 1, 1991 and October 11, 1992. The purpose of the study was to see if the addition of azathioprine would reduce the incidence of rejection and improve graft survival. The recipient population was unselected, with 61 (30%) patients undergoing retransplantation, 37 (18%) having a panel-reactive antibody greater than 40%, and 33 (16%) over 60 years of age. The mean recipient age was 43.8 +/- 13.7 years (range 17.6-78). The mean donor age was 34.0 +/- 20.1 years (range 0.3-75); 13% of the cadaveric kidneys were from pediatric donors less than 3 years of age and were transplanted en bloc. The mean cold ischemia time was 31.4 +/- 8.4 hr. Living donors were the source of 13% of the kidneys. The mean follow-up was 22 +/- 4 months (range 12-29). Overall one-year actual patient survival was 94%. Overall one-year actual graft survival was 87%. Patients starting on double therapy had a one-year actual patient survival of 96% and a one-year actual graft survival of 92%. Patients starting on triple therapy had a one-year actual patient survival of 91% (P = ns co...Continue Reading


Mar 27, 2001·Transplantation Proceedings·R ShapiroT E Starzl
Aug 15, 2002·Transplantation Proceedings·Johannes M M BootsJ P van Hooff
Feb 1, 1997·Transplantation Proceedings·R Shapiro
Feb 1, 1997·Transplantation Proceedings·R M NaraghiM L Jordan
Jun 24, 1998·Transplantation Proceedings·M L JordanT E Starzl
Dec 5, 1998·Transplantation Proceedings·H M ChengC S Li
Sep 29, 1999·Transplantation Proceedings·K TokiA Okuyama
Dec 1, 1999·Transplantation Proceedings·T TojimbaraT Agishi
Jan 5, 2000·Transplantation Proceedings·J P van Hooff, M H Christiaans
Nov 27, 1999·Transplantation Proceedings·M L JordanT E Starzl
Nov 27, 1999·Transplantation Proceedings·M L JordanT E Starzl
Dec 27, 1996·Transplantation·R ShapiroT E Starzl
Feb 1, 1997·Transplantation Proceedings·M L JordanT E Starzl
Feb 12, 1999·Transplantation·R ShapiroT E Starzl
Jul 4, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·R ShapiroT E Starzl
Feb 23, 2002·Current Opinion in Urology·Sabine SchmaldienstWalter H Hörl
Apr 7, 2006·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·M LoebeD J Hamilton
Jan 5, 2002·International Journal of Paediatric Dentistry·B WondimuT Modéer
Jun 30, 2000·Drugs & Aging·J M MoralesJ C Herrero
Jul 26, 2005·Drugs & Aging·Christine E Staatz, Susan E Tett
Mar 11, 2004·The Annals of Pharmacotherapy·Kazushige TakahashiKen-Ichi Inui
Mar 5, 2002·Diabetes Care·Victor M MontoriYogish C Kudva
Jul 17, 1998·Transplant International : Official Journal of the European Society for Organ Transplantation·I A Hauser, H N Neumayer
Jan 1, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Wesley HayesStephen D Marks
Feb 3, 1998·Transplantation·F J DumontM Wyvratt
Jul 27, 2001·Transplantation·J P SquiffletUNKNOWN European Tacrolimus-MMF Renal Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.